Effects of the platelet-derived growth factor/insulin-like growth factor-I combination on bone regeneration around titanium dental implants. Results of a pilot study in beagle dogs

• Published in: Journal of periodontology (1970) Vol. 62; no. 11; p. 710
• Main Authors: Lynch, S E, Buser, D, Hernandez, R A, Weber, H P, Stich, H, Fox, C H, Williams, R C
• Format: Journal Article
• Language: English
• Published: United States 01-11-1991
• Subjects: Analysis of Variance; Animals; Bone Regeneration - drug effects; Dental Implantation, Endosseous; Dental Implants; Dogs; Drug Combinations; Female; Gels; Insulin-Like Growth Factor I - administration & dosage; Insulin-Like Growth Factor I - therapeutic use; Mandible - pathology; Mandible - physiopathology; Mandible - surgery; Methylcellulose; Pilot Projects; Placebos; Platelet-Derived Growth Factor - administration & dosage; Platelet-Derived Growth Factor - therapeutic use; Recombinant Proteins; Titanium; Wound Healing
• ISSN: 0022-3492
• DOI: 10.1902/jop.1991.62.11.710

The purpose of this study was to evaluate the early wound healing events of bone around press-fit titanium implants inserted with and without the concurrent application of a combination of platelet-derived growth factor (PDGF) and insulin-like growth factor (IGF-I). Nine months prior to implant placement all mandibular premolar teeth were extracted in 8 beagle dogs. Subsequently, 40 specially manufactured titanium implants with 2 transverse holes in the apical section were press fit into precise recipient sites in the dogs' mandibles. The dogs were sacrificed at 7 and 21 days following implant placement yielding 12 PDGF-B/IGF-I treated and 8 control (placebo gel or non-treated) implants for each observation period. Coded undecalcified sections were analyzed for: 1) percentage of implant surface in contact with new bone; 2) percentage of peri-implant space filled with new bone; and 3) percentage of implant hole filled with new bone. An analysis of variance was used to determine significant differences among the treatment groups. At 7 days, the percentage of bone fill in the peri-implant spaces and the percentage of implant surface in contact with new bone were both significantly increased in PDGF-B/IGF-I treated sites (P less than 0.01 for both groups). There was less than 1.5% fill of the implant holes in both treated and control sites (no significant differences). At 21 days the percentage of bone fill in the peri-implant spaces was significantly increased in the PDGF-B/IGF-I treated sites (P less than 0.01).